The association of menopausal hormone levels with progression-related biomarkers in multiple sclerosis
Authors:
Open Access
- 28 February 2024
- journal article
- research article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 85, 105517
Abstract
No abstract availableKeywords
Funding Information
- Research Council of Finland
- Tampereen Yliopisto
- Maire Taponen Foundation
- Tays
This publication has 49 references indexed in Scilit:
- The impact of menopause on multiple sclerosisAutoimmunity Reviews, 2023
- Decreased neurofilament light chain levels in estriol‐treated multiple sclerosisAnnals of Clinical and Translational Neurology, 2022
- Diagnosis and Treatment of Multiple SclerosisJAMA, 2021
- Evaluating the Risk of Macrovascular Events and Mortality Among People With Multiple Sclerosis in EnglandJAMA Neurology, 2020
- Endocrinology of the MenopauseEndocrinology and Metabolism Clinics of North America, 2015
- Multiple sclerosis at menopause: Potential neuroprotective effects of estrogenMaturitas, 2015
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosisJournal of Neurology, 2011
- Sex hormones, brain damage and clinical course of Multiple SclerosisJournal of the Neurological Sciences, 2009
- Treatment of multiple sclerosis with the pregnancy hormone estriolAnnals of Neurology, 2002